Your Advocates Ltd’s Denali Therapeutics DNLI Stock Holding History

Your Advocates Ltd’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.92K	Hold	100	–	–	﹤0.01%	180
2025 Q4	$1.65K	Hold	100	–	–	﹤0.01%	186
2025 Q3	$1.45K	Hold	100	–	–	﹤0.01%	177
2025 Q2	$1.4K	Hold	100	–	–	﹤0.01%	167
2025 Q1	$1.36K	Hold	100	–	–	﹤0.01%	171
2024 Q4	$2.04K	Hold	100	–	–	﹤0.01%	162
2024 Q3	$2.91K	Hold	100	–	–	﹤0.01%	170
2024 Q2	$2.32K	Hold	100	–	–	﹤0.01%	176
2024 Q1	$2.05K	Hold	100	–	–	﹤0.01%	173
2023 Q4	$2.15K	Hold	100	–	–	﹤0.01%	169
2023 Q3	$2.06K	Hold	100	–	–	﹤0.01%	194
2023 Q2	$2.95K	Hold	100	–	–	﹤0.01%	197
2023 Q1	$2.3K	Hold	100	–	–	﹤0.01%	169
2022 Q4	$2.78K	Hold	100	–	–	﹤0.01%	143
2022 Q3	$3K	Hold	100	–	–	﹤0.01%	132
2022 Q2	$3K	Hold	100	–	–	﹤0.01%	137
2022 Q1	$3K	Hold	100	–	–	﹤0.01%	154
2021 Q4	$4K	Buy	+100	New	+$4.74K	﹤0.01%	129

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Your Advocates Ltd's DNLI Position: Q1 2026 in Review

Your Advocates Ltd held its Denali Therapeutics (DNLI) position steady in Q1 2026 at 100 shares worth $1.92K. The position accounts for ﹤0.01% of the portfolio, ranked #180.

Your Advocates Ltd first reported a position in DNLI in Q4 2021 and has held it in 18 quarters since. The position peaked at $4K in Q4 2021. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

Your Advocates Ltd held 100 shares of Denali Therapeutics worth $1.92K as of Q1 2026.
Your Advocates Ltd left its Denali Therapeutics share count unchanged in Q1 2026.
Denali Therapeutics made up ﹤0.01% of Your Advocates Ltd's portfolio in Q1 2026, its #180 holding.
Your Advocates Ltd first reported a position in Denali Therapeutics in Q4 2021 and has held it in 18 quarters since.
Your Advocates Ltd's Denali Therapeutics position peaked at $4K in Q4 2021.
268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Your Advocates Ltd's 13F filing for Q1 2026, filed 30 Apr 2026.